Literature DB >> 11880163

Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients.

C Farina1, V Vargas, N Heydari, T Kümpfel, E Meinl, R Hohlfeld.   

Abstract

We analysed the humoral immune response to glatiramer acetate (GA, Copaxone) in 20 multiple sclerosis patients treated with GA, 20 patients not treated with GA and 20 normal control subjects. Using an ELISA for detection of total GA-reactive immunoglobulins (all isotypes), all treated patients but also 3/20 untreated and 8/20 healthy subjects scored positive at 1:20 plasma dilutions. At higher dilutions, 5/20 treated patients and two healthy donors had relatively high levels of anti-GA antibodies. Isotype and IgG subclass analysis revealed that the two antibody-positive normal subjects had IgM and small titers of IgG1 or IgG2 antibodies. In contrast, 18 of 20 GA-treated patients, had low but significant titers of GA-reactive IgG4 antibodies. This finding is consistent with the previously described GA-mediated induction of T-helper 2 (TH2)-like regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880163     DOI: 10.1016/s0165-5728(01)00490-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  The Evolving Mechanisms of Action of Glatiramer Acetate.

Authors:  Thomas Prod'homme; Scott S Zamvil
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 3.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Authors:  Patrice H Lalive; Oliver Neuhaus; Mahdia Benkhoucha; Danielle Burger; Reinhard Hohlfeld; Scott S Zamvil; Martin S Weber
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

Review 5.  Biomaterial strategies for generating therapeutic immune responses.

Authors:  Sean H Kelly; Lucas S Shores; Nicole L Votaw; Joel H Collier
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

Review 6.  B cells and antibodies in multiple sclerosis pathogenesis and therapy.

Authors:  Markus Krumbholz; Tobias Derfuss; Reinhard Hohlfeld; Edgar Meinl
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

Review 7.  Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Authors:  Martin S Weber; Reinhard Hohlfeld; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 8.  Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

Authors:  Florian Deisenhammer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Immediate reactions with glatiramer acetate: Diagnosis of allergy and desensitization protocols.

Authors:  Guadalupe Marco-Martín; Pilar Tornero; Alicia Prieto; Alejandro La Rotta; Teresa Herrero; Maria Luisa Baeza
Journal:  Neurol Clin Pract       Date:  2020-04

10.  Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.

Authors:  Oscar Fernández
Journal:  J Cent Nerv Syst Dis       Date:  2012-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.